These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26617339)

  • 1. Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin.
    Naik H; Czerniak R; Vakilynejad M
    Br J Clin Pharmacol; 2016 Apr; 81(4):700-12. PubMed ID: 26617339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
    Dudkowski C; Tsai M; Liu J; Zhao Z; Schmidt E; Xie J
    Eur J Clin Pharmacol; 2017 Mar; 73(3):279-288. PubMed ID: 27999883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of imigliptin, its five metabolites and alogliptin in human plasma and urine and its application to a multiple-dose pharmacokinetic study.
    Liu Y; Song L; Yao X; Wu Y; Liu H; Zhao Q; Jiang J; Shi C; Ma X; Zhou H; Liu D; Hu P
    Biomed Chromatogr; 2018 Nov; 32(11):e4324. PubMed ID: 29952007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
    Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
    Karim A; Laurent A; Munsaka M; Wann E; Fleck P; Mekki Q
    J Clin Pharmacol; 2009 Oct; 49(10):1210-9. PubMed ID: 19622714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):1005-20. PubMed ID: 25936384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
    Jain L; Chain ASY; Tatosian DA; Hing J; Passarell JA; Kauh EA; Lai E
    Br J Clin Pharmacol; 2019 Dec; 85(12):2759-2771. PubMed ID: 31454094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
    Tebboth A; Lee S; Scowcroft A; Bingham-Gardiner P; Spencer W; Bolodeoku J; Hassan SW
    Clin Ther; 2016 Aug; 38(8):1825-1832.e15. PubMed ID: 27491279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes.
    Hu J; Yang C; Wang H; Li J; Tan X; Wang J; Zhang B; Zhao Y
    Expert Opin Pharmacother; 2019 Oct; 20(14):1679-1687. PubMed ID: 31335214
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
    Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
    Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1225-38. PubMed ID: 26218204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alogliptin for the treatment of type 2 diabetes.
    White JR
    Drugs Today (Barc); 2011 Feb; 47(2):99-107. PubMed ID: 21431099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF
    Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alogliptin benzoate for the treatment of type 2 diabetes.
    Seino Y; Yabe D
    Expert Opin Pharmacother; 2014 Apr; 15(6):851-63. PubMed ID: 24646052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes.
    Takebayashi K; Sakurai S; Suzuki T; Hori K; Terasawa T; Naruse R; Hara K; Suetsugu M; Tsuchiya T; Aoki H; Hamasaki T; Shuutou H; Inukai T
    Endocr J; 2014; 61(10):1031-9. PubMed ID: 25185672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alogliptin benzoate for management of type 2 diabetes.
    Saisho Y
    Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
    Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function.
    Duong JK; Kumar SS; Kirkpatrick CM; Greenup LC; Arora M; Lee TC; Timmins P; Graham GG; Furlong TJ; Greenfield JR; Williams KM; Day RO
    Clin Pharmacokinet; 2013 May; 52(5):373-84. PubMed ID: 23475568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
    Karim A; Covington P; Christopher R; Davenport M; Fleck P; Li X; Wann E; Mekki Q
    Int J Clin Pharmacol Ther; 2010 Jan; 48(1):46-58. PubMed ID: 20040339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alogliptin benzoate for the treatment of type 2 diabetes.
    Rendell M; Drincic A; Andukuri R
    Expert Opin Pharmacother; 2012 Mar; 13(4):553-63. PubMed ID: 22296609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.